Treatment of endocrine pancreatic tumors

Fjällskog, Marie-Louise; Janson, Eva Tiensuu

doi:10.1080/02841860510029941

Cited by 5 publications

(6 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today first-line medical treatment of EPTs is chemotherapy [16]. Pietras et al have shown that PDGFR beta antagonists can be used to decrease IFP thereby increasing drug uptake hence improving effectiveness of chemotherapy [11 Á13].…”

Section: Discussionmentioning

confidence: 99%

Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

et al. 2007

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

et al. 2007

Self Cite

View full text Add to dashboard Cite

“…The functioning tumors are divided into insulinomas [6], gastrinomas [7], glucagonomas [8], and VIPomas [9]. The only curative therapy is surgical resection of the pNET [10], but metastases are often present at diagnosis [2]. For these patients, medical treatment (chemotherapy, interferon or somatostatin analogs) has been available in recent decades [10].…”

Section: Introductionmentioning

confidence: 99%

“…The only curative therapy is surgical resection of the pNET [10], but metastases are often present at diagnosis [2]. For these patients, medical treatment (chemotherapy, interferon or somatostatin analogs) has been available in recent decades [10]. The established first-line treatment in our department has been the combination of streptozocin (STZ) and 5-fluorouracil (5-FU) with radiologically objective responses in one third of the patients [11,12,13].…”

Section: Introductionmentioning

confidence: 99%

Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity

et al. 2015

View full text Add to dashboard Cite

Background: In our center,the combination of streptozocin (STZ) and 5-fluorouracil (5-FU) has been used as the first-line treatment in the majority of patients with pancreatic neuroendocrine tumors (pNETs) over the past few decades. The objective of the current study was to assess the efficacy, prognostic factors and safety of the combination of STZ and 5-FU. Patients and Methods: Medical records and radiological reports of 133 patients with pNETs who received the combination of STZ and 5-FU during the period 1981-2014 were retrospectively evaluated. Results: The median survival from the start of treatment was 51.9 months in the whole group. In the radiologically evaluable patients (n = 100), progression-free survival was 23 months. Complete response was reached in 3 patients (3%), partial response in 25 patients (25%), 64 patients (64%) had stable disease, and 8 patients (8%) had progressive disease. In a multivariate analysis, surgery of the primary tumor and having a G3 tumor were significant positive and negative prognostic factors of survival from the start of treatment, respectively. Having either a G3 tumor or a stage IV tumor were significant prognostic factors for a shorter progression-free survival. Chemotherapy had to be discontinued in 29 patients due to side effects, of which kidney toxicity (mainly grades 1-2) was the most frequent. Conclusion: As shown in recent reports, the combination of STZ and 5-FU is effective in the treatment of pNETs in terms of survival and radiological response and has an acceptable toxicity profile.

show abstract

“…[18][19][20][21][22][23] Currently, surgical resection is the only curative therapeutic approach. [24] For patients with unresectable disease, numerous therapies are available, including interferon, somatostatin analogs, chemotherapy with streptozocin (STZ) plus 5-fluorouracil (5-FU) or temozolomide plus capecitabine, targeted therapies with everolimus or sunitinib, and peptide receptor radionuclide therapy. [24][25][26][27][28][29][30] According to current guidelines, systemic chemotherapy with STZ/5-FU is the standard first-line therapy to induce disease control in patients with advanced pNETs not amenable to resection.…”

Section: Introductionmentioning

confidence: 99%

“…Prognostic factors for patients with pNETs include age, performance status, tumor stage, serum chromogranin A levels, and the tumor proliferation marker Ki-67, whereas predictive markers are still lacking [18–23] . Currently, surgical resection is the only curative therapeutic approach [24] . For patients with unresectable disease, numerous therapies are available, including interferon, somatostatin analogs, chemotherapy with streptozocin (STZ) plus 5-fluorouracil (5-FU) or temozolomide plus capecitabine, targeted therapies with everolimus or sunitinib, and peptide receptor radionuclide therapy [24–30] .…”

Section: Introductionmentioning

confidence: 99%

Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors

et al. 2022

View full text Add to dashboard Cite

Rationale: Pancreatic neuroendocrine tumors (pNETs) are rare entities representing 1% to 3% of all malignant pancreatic neoplasms. Current guidelines recommend a combination of streptozocin (STZ) and 5-fluorouracil (5-FU) for patients with metastatic well-differentiated pNETs requiring systemic therapy. The highest median progression-free survival rate reported in previous studies for this combination was 23 months (95% confidence interval 14.5–31.5). However, it remains unclear for how long this regimen can be safely administered. Patient concerns: We report about 3 therapy-naïve patients with metastatic G2 (Ki67 10%–15%) pNETs treated with STZ/5-FU, that achieved sustained disease control for longer than 36 months. Diagnosis: Metastatic, well-differentiated G2 pNETs Interventions: Systemic chemotherapy with STZ/5-FU was administered until the disease progressed. In 1 case showing a mixed response, selected metastases of increasing size were additionally treated with surgery and brachytherapy. Outcomes: In our 3 patients with metastatic G2 pNETs, STZ/5-FU induced long-term disease control over 44, 42, and 95 months, respectively. No side effects that led to treatment discontinuation were observed. Lessons: In patients with metastatic G2 pNETs achieving disease control, STZ/5-FU can be safely administered.

show abstract

Treatment of endocrine pancreatic tumors

Cited by 5 publications

References 81 publications

Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity

Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors

Contact Info

Product

Resources

About